Dimethyl DL-Glutamate (hydrochloride)
(Synonyms: DL-谷氨酸二甲酯盐酸盐,Glutamic Acid dimethyl ester,Dimethyl 2-aminopentanedioate) 目录号 : GC15286A cell-permeant glutamate derivative
Cas No.:13515-99-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Dimethyl DL-glutamate is a cell-permeable form of glutamate.
Extracellular glutamic acid is an excitatory neurotransmitter, while intracellular glutamic acid is an amino acid that serves various metabolic roles.
In vitro: Dimethyl DL-glutamate at 3.0-10.0 mM could enhance insulin release evoked by 6.0-8.3 mM D-glucose, 1.0-10.0 mM L-leucine, or 5.0-10.0 mM 2-amino-bicyclo(2,2,1)heptane-2-carboxylic acid, resulting in a shift to the left of the sigmoidal relationship between insulin output and D-glucose concentration. Moreover, dimethyl DL-glutamate unmasked the insulinotropic potential of glibenclamide in the absence of D-glucose. In islets exposed to L-leucine, the insulinotropic action of dimethyl DL-glutamate coincided with an early fall and later increase in 86Rb outflow. In addition, the overall gain in O2 uptake represented the balance between dimethyl DL-glutamate oxidation and its sparing action on the catabolism of endogenous fatty acids and exogenous D-glucose [1].
In vivo: Dimethyl DL-glutamate was intravenously administered as a primed constant infusion to adult rats that had been injected with streptozotocin during the neonatal period. Results showed that dimethyl DL-glutamate augmented plasma insulin concentration and potentiated and/or prolonged the insulinotropic action of GLP-1 injected intravenously at min 5 of the test [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Sener, A. ,Conget, I.,Rasschaert, J., et al. Insulinotropic action of glutamic acid dimethyl ester. American Journal of Physiology 267(4 Pt 1), E573-E584 (1994).
[2] Cancelas, J. ,Villaneuva-Peacarrillo, M.L.,Valverde, I., et al. Potentiation and prolongation of the insulinotropic action of glucagon-like peptide 1 by methyl pyruvate or dimethyl ester of L-glutamic acid in a type 2 diabetes animal model. Endocrine 16(2), 113-116 (2001).
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.7259 mL | 23.6295 mL | 47.259 mL |
5 mM | 0.9452 mL | 4.7259 mL | 9.4518 mL |
10 mM | 0.4726 mL | 2.3629 mL | 4.7259 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。